Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

83 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment and clinical management of primary mediastinal large B-cell lymphoma with sclerosis: MACOP-B regimen and mediastinal radiotherapy monitored by (67)Gallium scan in 50 patients.
Zinzani PL, Martelli M, Magagnoli M, Pescarmona E, Scaramucci L, Palombi F, Bendandi M, Martelli MP, Ascani S, Orcioni GF, Pileri SA, Mandelli F, Tura S. Zinzani PL, et al. Among authors: palombi f. Blood. 1999 Nov 15;94(10):3289-93. Blood. 1999. PMID: 10552937 Free article. Clinical Trial.
How do patients with aggressive non-Hodgkin's lymphoma treated with third-generation regimens (MACOP-B and F-MACHOP) fare in the long-term?
Zinzani PL, Martelli M, Magagnoli M, Zaja F, Storti S, Pavone E, Lauta VM, De Renzo A, Gobbi M, Bocchia M, Ronconi F, Scaramucci L, Gherlinzoni F, Palombi F, Bendandi M, Stefoni V, Anticoli Borza P, Cellini C, Mandelli F, Tura S. Zinzani PL, et al. Among authors: palombi f. Haematologica. 1999 Nov;84(11):996-1001. Haematologica. 1999. PMID: 10553159 Clinical Trial.
Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study).
Rigacci L, Battistini R, Kovalchuk S, Zoli V, Puccini B, Evangelista A, Arcaini L, Flenghi L, Visco C, Mian M, Di Rocco A, Peracchio C, Gotti M, Tisi MC, Palombi F, Pozzi S, Gioia D, Viero P, Martelli M. Rigacci L, et al. Among authors: palombi f. Hematol Oncol. 2022 Oct;40(4):609-616. doi: 10.1002/hon.3028. Epub 2022 Jun 5. Hematol Oncol. 2022. PMID: 35612350 Clinical Trial.
Pain syndromes in haematological malignancies: an overview.
Niscola P, Arcuri E, Giovannini M, Scaramucci L, Romani C, Palombi F, Trapè G, Morabito F. Niscola P, et al. Among authors: palombi f. Hematol J. 2004;5(4):293-303. doi: 10.1038/sj.thj.6200530. Hematol J. 2004. PMID: 15297845 Review.
MiR-22, a serum predictor of poor outcome and therapy response in diffuse large B-cell lymphoma patients.
Rinaldi F, Marchesi F, Palombi F, Pelosi A, Di Pace AL, Sacconi A, Terrenato I, Annibali O, Tomarchio V, Marino M, Cantonetti M, Vaccarini S, Papa E, Moretta L, Bertoni F, Mengarelli A, Regazzo G, Rizzo MG. Rinaldi F, et al. Among authors: palombi f. Br J Haematol. 2021 Nov;195(3):399-404. doi: 10.1111/bjh.17734. Epub 2021 Jul 28. Br J Haematol. 2021. PMID: 34318932
Dose-dense ABVD as first-line therapy in early-stage unfavorable Hodgkin lymphoma: results of a prospective, multicenter double-step phase II study by Fondazione Italiana Linfomi.
Santoro A, Mazza R, Spina M, Califano C, Specchia G, Carella M, Consoli U, Palombi F, Musso M, Pulsoni A, Kovalchuk S, Bonfichi M, Ricci F, Fabbri A, Liberati AM, Rodari M, Giordano L, Chimienti E, Balzarotti M, Sorasio R, Gallamini A, Ghiggi C, Ciammella P, Ricardi U, Chauvie S, Carlo-Stella C, Merli F. Santoro A, et al. Among authors: palombi f. Ann Hematol. 2021 Oct;100(10):2547-2556. doi: 10.1007/s00277-021-04604-x. Epub 2021 Jul 30. Ann Hematol. 2021. PMID: 34327561 Clinical Trial.
Evaluation of risk of symptomatic cytomegalovirus reactivation in myeloma patients treated with tandem autologous stem cell transplantation and novel agents: a single-institution study.
Marchesi F, Pimpinelli F, Dessanti ML, Gumenyuk S, Palombi F, Pisani F, Romano A, Spadea A, Maschio M, Ensoli F, Mengarelli A. Marchesi F, et al. Among authors: palombi f. Transpl Infect Dis. 2014 Dec;16(6):1032-8. doi: 10.1111/tid.12309. Epub 2014 Nov 5. Transpl Infect Dis. 2014. PMID: 25369809
BEAM vs FEAM high-dose chemotherapy: retrospective study in lymphoma patients undergoing autologous stem cell transplant.
Marchesi F, Capria S, Giannarelli D, Trisolini SM, Ansuinelli M, Caputo MD, Serrao A, Gumenyuk S, Renzi D, Pupo L, Palombi F, Provenzano I, Di Rocco A, Pisani F, Romano A, Spadea A, Papa E, Canfora M, Cantonetti M, Mengarelli A. Marchesi F, et al. Among authors: palombi f. Bone Marrow Transplant. 2018 Aug;53(8):1051-1054. doi: 10.1038/s41409-018-0120-x. Epub 2018 Feb 13. Bone Marrow Transplant. 2018. PMID: 29440737 No abstract available.
Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study.
Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG. Marchesi F, et al. Among authors: palombi f. J Exp Clin Cancer Res. 2018 May 2;37(1):95. doi: 10.1186/s13046-018-0768-5. J Exp Clin Cancer Res. 2018. PMID: 29716630 Free PMC article.
83 results